126 related articles for article (PubMed ID: 12663248)
1. Lamivudine resistant occult HBV: implications for public health?
Bowden S; Bartholomeusz A; Locarnini S
J Hepatol; 2003 Apr; 38(4):526-8. PubMed ID: 12663248
[No Abstract] [Full Text] [Related]
2. Hepatitis B viral genotypes and lamivudine resistance.
Kao JH; Liu CJ; Chen DS
J Hepatol; 2002 Feb; 36(2):303-4. PubMed ID: 11830346
[No Abstract] [Full Text] [Related]
3. Persistence of YMDD variants after withdrawal of Lamivudine.
van der Eijk AA; Niesters HG; Pas SD; de Man RA
J Hepatol; 2002 Feb; 36(2):304-5. PubMed ID: 11830347
[No Abstract] [Full Text] [Related]
4. [Lamivudine resistance impedes hepatitis B therapy].
Eggers HJ
Fortschr Med; 1997 Apr; 115(12):5. PubMed ID: 9235306
[No Abstract] [Full Text] [Related]
5. Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.
Kuwahara R; Kumashiro R; Inoue H; Tanabe R; Tanaka E; Hino T; Ide T; Koga Y; Sata M
Dig Dis Sci; 2004 Feb; 49(2):300-3. PubMed ID: 15104374
[No Abstract] [Full Text] [Related]
6. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?
Buti M; Cotrina M; Valdes A; Jardi R; Rodriguez-Frias F; Esteban R
J Hepatol; 2002 Mar; 36(3):445-6. PubMed ID: 11867193
[No Abstract] [Full Text] [Related]
7. Lamivudine for chemotherapy-induced reactivation of HBV: prophylaxis or treatment?
Mancuso A; Pagliaro L
Am J Gastroenterol; 2002 May; 97(5):1268-9. PubMed ID: 12014746
[No Abstract] [Full Text] [Related]
8. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus resistance to antivirals: clinical implications and management.
Zoulim F
J Hepatol; 2003; 39 Suppl 1():S133-8. PubMed ID: 14708691
[No Abstract] [Full Text] [Related]
10. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
van Bömmel F; Wünsche T; Schürmann D; Berg T
Hepatology; 2002 Aug; 36(2):507-8. PubMed ID: 12143063
[No Abstract] [Full Text] [Related]
11. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B.
Cainelli F; Longhi MS; Concia E; Vento S
Am J Gastroenterol; 2001 May; 96(5):1651-2. PubMed ID: 11374725
[No Abstract] [Full Text] [Related]
12. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
[TBL] [Abstract][Full Text] [Related]
13. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
Seehofer D; Rayes N; Steinmüller T; Müller AR; Settmacher U; Neuhaus R; Radke C; Berg T; Hopf U; Neuhaus P
Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
[TBL] [Abstract][Full Text] [Related]
14. Survival of infantile fulminant hepatitis B and treatment with Lamivudine.
Laubscher B; Gehri M; Roulet M; Wirth S; Gerner P
J Pediatr Gastroenterol Nutr; 2005 Apr; 40(4):518-20. PubMed ID: 15795605
[No Abstract] [Full Text] [Related]
15. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
Van Bömmel F; Schernick A; Hopf U; Berg T
Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
[No Abstract] [Full Text] [Related]
16. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
18. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
Mutimer D
J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
[No Abstract] [Full Text] [Related]
19. Primary infection with a lamivudine-resistant hepatitis B virus.
Thibault V; Aubron-Olivier C; Agut H; Katlama C
AIDS; 2002 Jan; 16(1):131-3. PubMed ID: 11741175
[No Abstract] [Full Text] [Related]
20. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count).
Haverkamp M; Smit M; Weersink A; Boucher CA; Hoepelman AI
AIDS; 2003 Jul; 17(10):1572-4. PubMed ID: 12824802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
